-
Scribe Therapeutics Adds $100M for Treatments for Neurodegeneration Diseases
Scribe Therapeutics is adding another $100 million to its coffers. The new funds will support the development of the company’s gene editing and delivery technologies and propel a pipeline of treatments for neurodegeneration and other diseases.
Will this initiative be different than past failed attempts at finding a cure for ALS?
Richard
-
0 Replies
-
Another article on this topic:
https://www.technologynetworks.com/genomics/blog/engineering-the-future-of-genetic-medicine-347275
Richard
Log in to reply.